HRAS and glioblastoma: To figure out the effect of Chr-A on viability and proliferation of human glioblastoma, we adopted a CCK8 assay first, and our results showed that Chr-A treatment for 48 h inhibited the growth of the U251 and U87-MG cells at different doses (Figure 2a), and the IC50 values were 0.475 μM and 1.77 μM, respectively.